Zivo Bioscience, Inc. financial data

Symbol
ZIVO, ZIVOW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
21 E. Long Lake Road, Suite 100, Bloomfield Hills, Michigan
State of incorporation
Nevada
Fiscal year end
December 31
Former names
HEALTH ENHANCEMENT PRODUCTS INC (to 10/16/2014), WESTERN GLORY HOLE INC (to 1/26/2004)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 28.2 % -77.2%
Debt-to-equity -148 % -140%
Return On Assets -677 % -155%
Operating Margin -10.4 K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.78 M shares -70.5%
Common Stock, Shares, Outstanding 2.79 M shares -70.4%
Entity Public Float 17.3 M USD -38.9%
Common Stock, Value, Issued 2.79 K USD -70.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 63.4 K USD
Revenue from Contract with Customer, Excluding Assessed Tax 63.4 K USD
Research and Development Expense 1.29 M USD -34.4%
General and Administrative Expense 5.3 M USD -21%
Operating Income (Loss) -6.57 M USD +24.3%
Nonoperating Income (Expense) -13.3 K USD +88%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -7.08 M USD +18.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.8 M USD -79.8%
Assets, Current 711 K USD -23.4%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 73.7 K USD -56%
Assets 816 K USD -27.6%
Accounts Payable, Current 706 K USD +5.31%
Accrued Liabilities, Current 1.29 M USD +128%
Liabilities, Current 3.09 M USD +10.6%
Long-term Debt and Lease Obligation 132 K USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 3.09 M USD +7.52%
Retained Earnings (Accumulated Deficit) -125 M USD -6.01%
Stockholders' Equity Attributable to Parent -2.27 M USD -30.3%
Liabilities and Equity 816 K USD -27.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.7 M USD +20.2%
Net Cash Provided by (Used in) Financing Activities 1.56 M USD +190%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 25 M shares -83.3%
Common Stock, Shares, Issued 2.38 M shares +51.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 274 K USD -84.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.06 K USD -13.5%
Deferred Tax Assets, Valuation Allowance 12.4 M USD +14.7%
Deferred Tax Assets, Gross 10.8 M USD +18.7%
Operating Lease, Liability 132 K USD -41%
Lessee, Operating Lease, Liability, to be Paid 142 K USD
Property, Plant and Equipment, Gross 100 K USD 0%
Operating Lease, Liability, Current 79 K USD -23.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 112 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 29.5 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.47 K USD -68.1%
Preferred Stock, Shares Issued 2.79 M shares -98.1%
Additional Paid in Capital 123 M USD +5.66%
Deferred Tax Assets, Net of Valuation Allowance 12.4 M USD +14.7%
Share-based Payment Arrangement, Expense 571 K USD -41.5%
Interest Expense 23.5 K USD +62.1%